Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · Real-Time Price · USD
45.05
+1.23 (2.81%)
Nov 4, 2024, 12:53 PM EST - Market open
Vera Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
51
Market Cap
2.47B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ACADIA Pharmaceuticals | 890.53M |
GoodRx Holdings | 775.09M |
iRhythm Technologies | 560.03M |
Twist Bioscience | 295.21M |
SpringWorks Therapeutics | 86.19M |
Arrowhead Pharmaceuticals | 19.65M |
IDEAYA Biosciences | 11.96M |
CG Oncology | 539.00K |
VERA News
- 5 days ago - Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock - GlobeNewsWire
- 6 days ago - Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock - GlobeNewsWire
- 7 days ago - Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years - Benzinga
- 8 days ago - Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 - GlobeNewsWire
- 4 weeks ago - Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients - Seeking Alpha
- 4 weeks ago - Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases - GlobeNewsWire
- 4 weeks ago - Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024 - GlobeNewsWire